Fanny Franchini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fanny Franchini has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Maarten J. Ijzerman
Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; Cancer Health Services Research, University of Melbourne, Australia; Erasmus School of Health Policy & Management, Rotterdam, The Netherlands
8 shared publications - Peter Gibbs
Division of Personalised Oncology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia
5 shared publications Benjamin J. Solomon
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
3 shared publications- Grant A. McArthur
Cancer Research Division and Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
3 shared publications - Jennifer A. Soon
Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; Cancer Health Services Research, University of Melbourne, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
3 shared publications - Jon Emery
Nanyang Technological University 5 Singapore
3 shared publications
Latest Publications
- Open Access
- 5 December 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 233, 116132
Current and emerging opportunities for deintensification of systemic therapies in melanoma: A scoping review
- 5 December 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 233, 116132
Open AccessCurrent and emerging opportunities for deintensification of systemic therapies in melanoma: A scoping review
- Open Access
- 27 December 2024
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 24 (1) , 1-12
Toward value-based care using cost mining: cost aggregation and visualization across the entire colorectal cancer patient pathway
Background: The aim of this study is to develop a method we call “cost mining” to unravel cost variation and identify cost drivers by modelling integrated patient pathways from primary care to the palliative care setting. This approach fills an urgent need to quantify financial strains on healthcare systems, particularly for colorectal cancer, which is the most expensive cancer in Australia, and the second most expensive cancer globally. Methods: We developed and published a customized algorithm that dynamically estimates and visualizes the mean, minimum, and total costs of care at the patient level, by aggregating activity-based healthcare system costs (e.g. DRGs) across integrated pathways. This extends traditional process mining approaches by making the resulting process maps actionable and informative and by displaying cost estimates. We demonstrate the method by constructing a unique dataset of colorectal cancer pathways in Victoria, Australia, using records of primary care, diagnosis, hospital admission and chemotherapy, medication, health system costs, and life events to create integrated colorectal cancer patient pathways from 2012 to 2020. Results: Cost mining with the algorithm enabled exploration of costly integrated pathways, i.e. drilling down in high-cost pathways to discover cost drivers, for 4246 cases covering approx. 4 million care activities. Per-patient CRC pathway costs ranged from $10,379 AUD to $41,643 AUD, and varied significantly per cancer stage such that e.g. chemotherapy costs in one cancer stage are different to the same chemotherapy regimen in a different stage. Admitted episodes were most costly, representing 93.34% or $56.6 M AUD of the total healthcare system costs covered in the sample. Conclusions: Cost mining can supplement other health economic methods by providing contextual, sequence and timing-related information depicting how patients flow through complex care pathways. This approach can also facilitate health economic studies informing decision-makers on where to target care improvement or to evaluate the consequences of new treatments or care delivery interventions. Through this study we provide an approach for hospitals and policymakers to leverage their health data infrastructure and to enable real time patient level cost mining.
- 27 December 2024
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 24 (1) , 1-12
Open AccessToward value-based care using cost mining: cost aggregation and visualization across the entire colorectal cancer patient pathway
Background: The aim of this study is to develop a method we call “cost mining” to unravel cost variation and identify cost drivers by modelling integrated patient pathways from primary care to the palliative care setting. This approach fills an urgent need to quantify financial strains on healthcare systems, particularly for colorectal cancer, which is the most expensive cancer in Australia, and the second most expensive cancer globally. Methods: We developed and published a customized algorithm that dynamically estimates and visualizes the mean, minimum, and total costs of care at the patient level, by aggregating activity-based healthcare system costs (e.g. DRGs) across integrated pathways. This extends traditional process mining approaches by making the resulting process maps actionable and informative and by displaying cost estimates. We demonstrate the method by constructing a unique dataset of colorectal cancer pathways in Victoria, Australia, using records of primary care, diagnosis, hospital admission and chemotherapy, medication, health system costs, and life events to create integrated colorectal cancer patient pathways from 2012 to 2020. Results: Cost mining with the algorithm enabled exploration of costly integrated pathways, i.e. drilling down in high-cost pathways to discover cost drivers, for 4246 cases covering approx. 4 million care activities. Per-patient CRC pathway costs ranged from $10,379 AUD to $41,643 AUD, and varied significantly per cancer stage such that e.g. chemotherapy costs in one cancer stage are different to the same chemotherapy regimen in a different stage. Admitted episodes were most costly, representing 93.34% or $56.6 M AUD of the total healthcare system costs covered in the sample. Conclusions: Cost mining can supplement other health economic methods by providing contextual, sequence and timing-related information depicting how patients flow through complex care pathways. This approach can also facilitate health economic studies informing decision-makers on where to target care improvement or to evaluate the consequences of new treatments or care delivery interventions. Through this study we provide an approach for hospitals and policymakers to leverage their health data infrastructure and to enable real time patient level cost mining.
- Open Access
- 10 December 2024
- Published by Springer Nature in British Journal of Cancer
- Vol. 132 (1) , 137
Correction: Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review
- 10 December 2024
- Published by Springer Nature in British Journal of Cancer
- Vol. 132 (1) , 137
Open AccessCorrection: Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review
- Open Access
Effects of clinical and socioeconomic factors on Medicare and patient costs for colorectal cancer in Australia: a retrospective multivariate regression analysis
Objective We study how clinical and socioeconomic factors influence colorectal cancer (CRC) costs for patients and Medicare in Australia. The study seeks to extend the limited Australian literature on CRC costs by analysing comprehensive patient-level medical services and pharmaceutical cost data. Design, setting and participants Using the Victorian Cancer Registry, we identified all patients in Victoria who were diagnosed with CRC from 2010 to 2019 and extracted their linked 2010–2021 Medicare data. This data includes expenses from the Pharmaceutical Benefits Scheme and Medicare Benefits Schedule services. We examined variables such as disease stage, CRC type, molecular profile, metastasis status and demographics (eg, age, birth country, socioeconomic level via the SEIFA index, and native language). We applied descriptive and log-linear multivariate regression analyses to explore patient and Medicare costs related to CRC treatment. Results Costs significantly rise with advanced cancer stages, especially on medication costs. Patients’ average out-of-pocket (OOP) expenses are roughly $A441 per year. Key cost influencers are gender, age and socioeconomic status. On average, males incur 13.5% higher annual costs, a significantly larger OOP expense, than females. Compared with patients aged 50 or below, there is a 7.1% cost increase for individuals aged 50–70 and an 8.8% decrease post-70, likely reflecting less intensive treatment for the elderly. Socioeconomic factors show a clear gradient. Wealthier areas experience higher costs, especially among native English speakers. Costs also vary based on cancer’s anatomical location and specific genetic mutations. Conclusion The research highlights that CRC treatment expenses for patients and Medicare differ considerably due to factors such as diagnostic stage, demographics, anatomical location of the tumour and mutations. These cost variations lead to concerns about healthcare equality and decision-making autonomy. Policymakers may need to focus on early detection, increased support for advanced-stage patients, gender-sensitive healthcare, and equitable access to treatment across different socioeconomic groups.
Open AccessEffects of clinical and socioeconomic factors on Medicare and patient costs for colorectal cancer in Australia: a retrospective multivariate regression analysis
Objective We study how clinical and socioeconomic factors influence colorectal cancer (CRC) costs for patients and Medicare in Australia. The study seeks to extend the limited Australian literature on CRC costs by analysing comprehensive patient-level medical services and pharmaceutical cost data. Design, setting and participants Using the Victorian Cancer Registry, we identified all patients in Victoria who were diagnosed with CRC from 2010 to 2019 and extracted their linked 2010–2021 Medicare data. This data includes expenses from the Pharmaceutical Benefits Scheme and Medicare Benefits Schedule services. We examined variables such as disease stage, CRC type, molecular profile, metastasis status and demographics (eg, age, birth country, socioeconomic level via the SEIFA index, and native language). We applied descriptive and log-linear multivariate regression analyses to explore patient and Medicare costs related to CRC treatment. Results Costs significantly rise with advanced cancer stages, especially on medication costs. Patients’ average out-of-pocket (OOP) expenses are roughly $A441 per year. Key cost influencers are gender, age and socioeconomic status. On average, males incur 13.5% higher annual costs, a significantly larger OOP expense, than females. Compared with patients aged 50 or below, there is a 7.1% cost increase for individuals aged 50–70 and an 8.8% decrease post-70, likely reflecting less intensive treatment for the elderly. Socioeconomic factors show a clear gradient. Wealthier areas experience higher costs, especially among native English speakers. Costs also vary based on cancer’s anatomical location and specific genetic mutations. Conclusion The research highlights that CRC treatment expenses for patients and Medicare differ considerably due to factors such as diagnostic stage, demographics, anatomical location of the tumour and mutations. These cost variations lead to concerns about healthcare equality and decision-making autonomy. Policymakers may need to focus on early detection, increased support for advanced-stage patients, gender-sensitive healthcare, and equitable access to treatment across different socioeconomic groups.
- Top Cited PapersOpen Access
- 3 November 2024
- Published by Springer Nature in British Journal of Cancer
- Vol. 132 (1) , 51-57
Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review
Background: Immune-related adverse events (irAE) induced by immune checkpoint inhibitors (ICI) are a treatment-limiting barrier. There are few large-scale studies that estimate irAE prevalence. This paper presents a systematic review that reports the prevalence of irAE by cancer type and ICI. Methods: A systematic review was undertaken in MEDLINE OVID, EMBASE and Web of Science databases from 2017–2021. A total of 293 studies were identified for analysis and, of these, event rate was calculated for 272 studies, which involved 58,291 patients with irAE among 305,879 total patients on ICI. Event rate was calculated by irAE and ICI type. Results: Mean event rate for general irAE occurrence across any grade was 40.0% (37.3–42.7%) and high grade was 19.7% (15.8–23.7%). Mean event rates for six specific types of irAE are reported. Mean event rate for ICI monotherapy was 30.5% (28.1–32.9%), 45.7% (29.6–61.7%) for ICI combination therapy, and 30.0% (25.3–34.6%) for both ICI monotherapy and combination therapy. Conclusion: This systematic review characterises irAE prevalence across current research that examines irAE risk factors across cancers and ICI. The findings confirms that irAE occurrence is very common in the real-world setting, both high grade and irAE across any grade.
- 3 November 2024
- Published by Springer Nature in British Journal of Cancer
- Vol. 132 (1) , 51-57
Top Cited PapersOpen AccessCancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review
Background: Immune-related adverse events (irAE) induced by immune checkpoint inhibitors (ICI) are a treatment-limiting barrier. There are few large-scale studies that estimate irAE prevalence. This paper presents a systematic review that reports the prevalence of irAE by cancer type and ICI. Methods: A systematic review was undertaken in MEDLINE OVID, EMBASE and Web of Science databases from 2017–2021. A total of 293 studies were identified for analysis and, of these, event rate was calculated for 272 studies, which involved 58,291 patients with irAE among 305,879 total patients on ICI. Event rate was calculated by irAE and ICI type. Results: Mean event rate for general irAE occurrence across any grade was 40.0% (37.3–42.7%) and high grade was 19.7% (15.8–23.7%). Mean event rates for six specific types of irAE are reported. Mean event rate for ICI monotherapy was 30.5% (28.1–32.9%), 45.7% (29.6–61.7%) for ICI combination therapy, and 30.0% (25.3–34.6%) for both ICI monotherapy and combination therapy. Conclusion: This systematic review characterises irAE prevalence across current research that examines irAE risk factors across cancers and ICI. The findings confirms that irAE occurrence is very common in the real-world setting, both high grade and irAE across any grade.
- 20 September 2024
- Published by Springer Nature in Nature Cancer
- Vol. 5 (11) , 1597-1599
Leveraging the potential for deintensification in cancer care
- 20 September 2024
- Published by Springer Nature in Nature Cancer
- Vol. 5 (11) , 1597-1599
Leveraging the potential for deintensification in cancer care
- Open Access
- 6 July 2024
- Published by Elsevier in Value in Health
- Vol. 27 (10) , 1382-1392
Predicting the Population Health Economic Impact of Current and New Cancer Treatments for Colorectal Cancer: A Data-Driven Whole Disease Simulation Model for Predicting the Number of Patients with Colorectal Cancer by Stage and Treatment Line in Australia
- 6 July 2024
- Published by Elsevier in Value in Health
- Vol. 27 (10) , 1382-1392
Open AccessPredicting the Population Health Economic Impact of Current and New Cancer Treatments for Colorectal Cancer: A Data-Driven Whole Disease Simulation Model for Predicting the Number of Patients with Colorectal Cancer by Stage and Treatment Line in Australia
- Open Access
- 20 November 2023
- Published by Elsevier in Journal of Cancer Policy
- Vol. 38, 100441
A tailored approach to horizon scanning for cancer medicines
- 20 November 2023
- Published by Elsevier in Journal of Cancer Policy
- Vol. 38, 100441
Open AccessA tailored approach to horizon scanning for cancer medicines
- Open Access
- 30 October 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1255021
Implementing competing risks in discrete event simulation: the event-specific probabilities and distributions approach
Background: Although several strategies for modelling competing events in discrete event simulation (DES) exist, a methodological gap for the event-specific probabilities and distributions (ESPD) approach when dealing with censored data remains. This study defines and illustrates the ESPD strategy for censored data.Methods: The ESPD approach assumes that events are generated through a two-step process. First, the type of event is selected according to some (unknown) mixture proportions. Next, the times of occurrence of the events are sampled from a corresponding survival distribution. Both of these steps can be modelled based on covariates. Performance was evaluated through a simulation study, considering sample size and levels of censoring. Additionally, an oncology-related case study was conducted to assess the ability to produce realistic results, and to demonstrate its implementation using both frequentist and Bayesian frameworks in R.Results: The simulation study showed good performance of the ESPD approach, with accuracy decreasing as sample sizes decreased and censoring levels increased. The average relative absolute error of the event probability (95%-confidence interval) ranged from 0.04 (0.00; 0.10) to 0.23 (0.01; 0.66) for 60% censoring and sample size 50, showing that increased censoring and decreased sample size resulted in lower accuracy. The approach yielded realistic results in the case study.Discussion: The ESPD approach can be used to model competing events in DES based on censored data. Further research is warranted to compare the approach to other modelling approaches for DES, and to evaluate its usefulness in estimating cumulative event incidences in a broader context.
- 30 October 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1255021
Open AccessImplementing competing risks in discrete event simulation: the event-specific probabilities and distributions approach
Background: Although several strategies for modelling competing events in discrete event simulation (DES) exist, a methodological gap for the event-specific probabilities and distributions (ESPD) approach when dealing with censored data remains. This study defines and illustrates the ESPD strategy for censored data.Methods: The ESPD approach assumes that events are generated through a two-step process. First, the type of event is selected according to some (unknown) mixture proportions. Next, the times of occurrence of the events are sampled from a corresponding survival distribution. Both of these steps can be modelled based on covariates. Performance was evaluated through a simulation study, considering sample size and levels of censoring. Additionally, an oncology-related case study was conducted to assess the ability to produce realistic results, and to demonstrate its implementation using both frequentist and Bayesian frameworks in R.Results: The simulation study showed good performance of the ESPD approach, with accuracy decreasing as sample sizes decreased and censoring levels increased. The average relative absolute error of the event probability (95%-confidence interval) ranged from 0.04 (0.00; 0.10) to 0.23 (0.01; 0.66) for 60% censoring and sample size 50, showing that increased censoring and decreased sample size resulted in lower accuracy. The approach yielded realistic results in the case study.Discussion: The ESPD approach can be used to model competing events in DES based on censored data. Further research is warranted to compare the approach to other modelling approaches for DES, and to evaluate its usefulness in estimating cumulative event incidences in a broader context.
- Open Access
- 11 October 2023
- Published by Swansea University in International Journal of Population Data Science
- Vol. 8 (6)
Data Resource Profile: Transforming Outcomes through Research in Cancer Healthcare in Victoria (TORCH-VIC)
IntroductionThe Transforming Outcomes through Research in Cancer Healthcare in Victoria (TORCH-VIC) is a comprehensive population-based cohort that links cancer diagnoses recorded in the Victorian Cancer Registry with administrative health data to capture the complete cancer journey from pre-diagnosis through long-term outcomes. Established in 2022, TORCH-VIC provides real-world evidence on healthcare utilisation, patterns of care, costs, and outcomes across the cancer continuum in Victoria, Australia. MethodsTORCH-VIC comprises adults aged 18 years and over diagnosed with colorectal, lung, melanoma, prostate, breast cancer, and lymphoid leukaemia in Victoria, Australia, between January 2010 and December 2021, identified through the Victorian Cancer Registry. Cross-jurisdictional linkage of 11 data collections was performed by the Centre for Victorian Data Linkage for state datasets (hospital admissions, emergency presentations, radiotherapy, outpatient services, elective surgery, costs, and deaths) and the Australian Institute of Health and Welfare Data Linkage Unit for national datasets (Pharmaceutical Benefits Scheme (PBS), Medicare Benefits Schedule (MBS), National Death Index). Annual refresh ensures ongoing data currency. ResultsThe dataset contains 222,332 unique individuals with 237,089 cancer diagnoses, stored securely in the Secure Unified Research Environment (SURE). Linkage rates exceed 98% for PBS and MBS data, with comprehensive inpatient hospital coverage (98.7%). The dataset captures over 250 million healthcare interactions across four phases: pre-diagnosis pathways, diagnosis, interventions, and outcomes. Data domains include socio-demographics, mortality, comorbidities, healthcare services, medicines, and costs. Mortality is comprehensively captured through linked state and national death registries (35.0% of cohort deceased). Loss to follow-up is minimal (1%), occurring primarily among individuals who emigrate or are ineligible for Medicare, with national datasets ensuring continued follow-up for those who relocate interstate within Australia. ConclusionTORCH-VIC enables research on cancer epidemiology, health service delivery, disparities in access, supportive care utilisation, survivorship, and healthcare costs. Applications span health services research, policy evaluation, and outcomes assessment. With ethics approvals secured, 2026 enhancements will add screening registers, immunisation data, and additional cancer types. Researchers interested in collaboration should contact the corresponding author to discuss projects within the study scope and ethics requirements.
- 11 October 2023
- Published by Swansea University in International Journal of Population Data Science
- Vol. 8 (6)
Open AccessData Resource Profile: Transforming Outcomes through Research in Cancer Healthcare in Victoria (TORCH-VIC)
IntroductionThe Transforming Outcomes through Research in Cancer Healthcare in Victoria (TORCH-VIC) is a comprehensive population-based cohort that links cancer diagnoses recorded in the Victorian Cancer Registry with administrative health data to capture the complete cancer journey from pre-diagnosis through long-term outcomes. Established in 2022, TORCH-VIC provides real-world evidence on healthcare utilisation, patterns of care, costs, and outcomes across the cancer continuum in Victoria, Australia. MethodsTORCH-VIC comprises adults aged 18 years and over diagnosed with colorectal, lung, melanoma, prostate, breast cancer, and lymphoid leukaemia in Victoria, Australia, between January 2010 and December 2021, identified through the Victorian Cancer Registry. Cross-jurisdictional linkage of 11 data collections was performed by the Centre for Victorian Data Linkage for state datasets (hospital admissions, emergency presentations, radiotherapy, outpatient services, elective surgery, costs, and deaths) and the Australian Institute of Health and Welfare Data Linkage Unit for national datasets (Pharmaceutical Benefits Scheme (PBS), Medicare Benefits Schedule (MBS), National Death Index). Annual refresh ensures ongoing data currency. ResultsThe dataset contains 222,332 unique individuals with 237,089 cancer diagnoses, stored securely in the Secure Unified Research Environment (SURE). Linkage rates exceed 98% for PBS and MBS data, with comprehensive inpatient hospital coverage (98.7%). The dataset captures over 250 million healthcare interactions across four phases: pre-diagnosis pathways, diagnosis, interventions, and outcomes. Data domains include socio-demographics, mortality, comorbidities, healthcare services, medicines, and costs. Mortality is comprehensively captured through linked state and national death registries (35.0% of cohort deceased). Loss to follow-up is minimal (1%), occurring primarily among individuals who emigrate or are ineligible for Medicare, with national datasets ensuring continued follow-up for those who relocate interstate within Australia. ConclusionTORCH-VIC enables research on cancer epidemiology, health service delivery, disparities in access, supportive care utilisation, survivorship, and healthcare costs. Applications span health services research, policy evaluation, and outcomes assessment. With ethics approvals secured, 2026 enhancements will add screening registers, immunisation data, and additional cancer types. Researchers interested in collaboration should contact the corresponding author to discuss projects within the study scope and ethics requirements.